Ligand Pharmaceuticals Inc (NASDAQ:LGND)
| 75.29 Delayed Data As of Jun 02 |  +4.09 / +5.74%Today’s Change | 45.25 Today|||52-Week Range 85.70 | +12.71% Year-to-Date |
Latest LGND News | Press Releases
Today’s Trading
| Previous close | 71.20 |
| Today’s open | 71.73 |
| Day’s range | 71.16 - 75.41 |
| Volume | 4,990 |
| Average volume (3 months) | 111,844 |
| Market cap | $1.2B |
Data as of 3:59pm ET, 06/02/2023
Growth & Valuation
| Earnings growth (last year) | -157.56% |
| Earnings growth (this year) | +79.30% |
| Earnings growth (next 5 years) | +20.00% |
| Revenue growth (last year) | -29.19% |
| P/E ratio | 26.1 |
| Price/Sales | 5.74 |
| Price/Book | 2.04 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| CPRXCatalyst Pharmaceuti... | -0.09 | -0.77% |
| CTICCTI Biopharma Corp | -0.01 | -0.11% |
| SMMTSummit Therapeutics ... | +0.09 | +5.26% |
| MNKDMannKind Corp | -0.03 | -0.56% |
Data as of 4:00pm ET, 06/02/2023
Financials
| Next reporting date | August 7, 2023 |
| EPS forecast (this quarter) | $0.63 |
| Annual revenue (last year) | $196.2M |
| Annual profit (last year) | -$33.4M |
| Net profit margin | -2.66% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters San Diego, California |
Forecasts
